Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sublingual immunotherapy (SLIT) by Anallergo is an allergen-specific immunotherapy product designed to treat allergic diseases such as allergic rhinitis and asthma. The therapy involves administering small doses of specific allergens under the tongue in the form of drops or tablets, with the goal of inducing immune tolerance to those allergens over time. The mechanism of action relies on promoting a shift from a Th2-dominated immune response (which drives allergy symptoms) toward a Th1/regulatory T cell response, increasing production of anti-inflammatory cytokines like IL-10 and TGF-beta. This leads to reduced sensitivity to allergens and decreased symptoms upon exposure[6][8]. Allergen-specific IgG and IgA antibodies are also induced, which block allergen-IgE complex formation[6]. Anallergo develops customized formulations for individual patients based on their specific allergies[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on allergen extract (Anallergo SLIT).